LTB4

Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit

Retrieved on: 
Tuesday, March 5, 2024
Therapy, DLA Piper, Leukotriene B4, NEI, C5, CNV, OTC, Inflammation, Bayer, Choroidal neovascularization, ADC, Risk, AATD, American depositary receipt, Geographic atrophy, Haematopoietic system, Patient, Autoimmunity, McKinsey & Company, Hot game, LTB4, Cancer, Pharmaceutical industry

Following closing, the company will have an expanded pipeline that contains multiple compelling assets spanning early and late development stages.

Key Points: 
  • Following closing, the company will have an expanded pipeline that contains multiple compelling assets spanning early and late development stages.
  • An assessment of the pipeline is planned, including program prioritization, updated timelines, near-term value creation opportunities, and other considerations.
  • Key highlights of the merger include:
    The merged pipeline features a robust ADC toolkit with novel payload and linker technologies.
  • Goodwin Procter LLP is serving as legal advisor to Akari and DLA Piper LLP is serving as legal advisor to Peak Bio.

Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit

Retrieved on: 
Tuesday, March 5, 2024
Therapy, DLA Piper, Leukotriene B4, NEI, C5, CNV, OTC, Inflammation, Bayer, Choroidal neovascularization, ADC, Risk, AATD, American depositary receipt, Geographic atrophy, Haematopoietic system, Patient, Autoimmunity, McKinsey & Company, Hot game, LTB4, Cancer, Pharmaceutical industry

Following closing, the company will have an expanded pipeline that contains multiple compelling assets spanning early and late development stages.

Key Points: 
  • Following closing, the company will have an expanded pipeline that contains multiple compelling assets spanning early and late development stages.
  • An assessment of the pipeline is planned, including program prioritization, updated timelines, near-term value creation opportunities, and other considerations.
  • Key highlights of the merger include:
    The merged pipeline features a robust ADC toolkit with novel payload and linker technologies.
  • Goodwin Procter LLP is serving as legal advisor to Akari and DLA Piper LLP is serving as legal advisor to Peak Bio.

Akari Therapeutics Presents Poster on Progress in Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference

Retrieved on: 
Thursday, November 16, 2023
Eye, Leukotriene B4, Intravitreal injection, Therapy, Risk, Choroidal neovascularization, CNV, Akari, Hot game, LTB4, Geographic atrophy, C5, Poster, Pharmaceutical industry

BOSTON and LONDON, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the presentation of progress in the development of long-acting PASylated®-nomacopan as a potential treatment for geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD) in a poster at the 4th Annual Dry AMD Therapeutic Development conference.

Key Points: 
  • BOSTON and LONDON, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the presentation of progress in the development of long-acting PASylated®-nomacopan as a potential treatment for geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD) in a poster at the 4th Annual Dry AMD Therapeutic Development conference.
  • The poster was presented by Akari Chief Scientific Officer Miles Nunn on November 15, 2023.
  • The poster can be viewed on the Akari website at akaritx.com.
  • “Part of this progress is the advancement of a high yield manufacturing process that supports our program moving into clinical trials in 2024.”
    Long-acting PAS-nomacopan is a bispecific inhibitor of complement C5 and leukotriene B4 (LTB4).

Akari Therapeutics to Present a Poster on Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference

Retrieved on: 
Monday, November 6, 2023
Choroidal neovascularization, CNV, Intravitreal injection, C5, Treatment, Geographic atrophy, Poster, Leukotriene B4, Hot game, LTB4, Therapy, Pharmaceutical industry

BOSTON and LONDON, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that Chief Scientific Officer Miles Nunn will present a poster titled Development of PASylated®-Nomacopan for Treatment of Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (dAMD) at the 4th Annual Dry AMD Therapeutic Development conference taking place November 14-16 in Boston, MA.

Key Points: 
  • BOSTON and LONDON, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that Chief Scientific Officer Miles Nunn will present a poster titled Development of PASylated®-Nomacopan for Treatment of Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (dAMD) at the 4th Annual Dry AMD Therapeutic Development conference taking place November 14-16 in Boston, MA.
  • The poster will be presented on November 15, 2023 at 3:00 pm ET.
  • Long-acting PAS-nomacopan is a bispecific inhibitor of complement C5 and leukotriene B4 (LTB4).
  • It is in the final stages of pre-clinical development as a potential treatment for GA with the goals of providing a longer dose interval between intravitreal injections and reduction of choroidal neovascularization (CNV) risk associated with approved complement-only inhibitors currently used in GA treatment.

Akari Therapeutics Reports First Half 2023 Financial Results and Highlights

Retrieved on: 
Friday, September 29, 2023
Consensus, Manchester University NHS Foundation Trust, EBMT, Male, PRV, Ministry of Health (Poland), Medical device, IMPD, Civil service commission, Leukotriene B4, Blood, Priority review, Marketing, Health care, Clinical trial, Pediatrics, Royal Manchester Children's Hospital, Geographic atrophy, Committee on Herbal Medicinal Products, CTA, Medication, GA, Type, HSCT, Hot game, Hematopoietic stem cell transplantation, European Commission, Patient, NHS foundation trust, Akari, CFO, Diagnosis, Poster, Hospital, Regulatory affairs, European Society for Medical Oncology, FDA, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, LTB4, Food, Autoimmunity, Safety, C5, Inflammation, Pharmaceutical industry, Nursing

Adult study design will be an important topic of discussion during a Type C meeting with the U.S. Food and Drug Administration (FDA) scheduled for November 15, 2023.

Key Points: 
  • Adult study design will be an important topic of discussion during a Type C meeting with the U.S. Food and Drug Administration (FDA) scheduled for November 15, 2023.
  • Akari was granted orphan drug designation from the European Commission for treatment in hematopoietic stem cell transplantation.
  • Akari also selected Wacker Biotech GmbH as the manufacturing partner to support production of PAS-nomacopan for use in clinical trials.
  • Akari appointed experienced life sciences executive Wendy DiCicco as interim Chief Financial Officer (CFO).

Akari Therapeutics to Present at Emerging Growth Conference

Retrieved on: 
Wednesday, September 27, 2023
Growth, Hot game, Therapy, Leukotriene B4, LTB4, Conference, C5, Pharmaceutical industry

BOSTON and LONDON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that the company will participate in the Emerging Growth Conference being held October 4 and 5, 2023.

Key Points: 
  • BOSTON and LONDON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that the company will participate in the Emerging Growth Conference being held October 4 and 5, 2023.
  • President and CEO Rachelle Jacques will present an overview of the company and its lead asset nomacopan, a bispecific inhibitor of complement C5 and leukotriene B4 (LTB4), on October 4, 2023 from 11:25 am to 11:55 am ET.

Akari Therapeutics to Host Key Opinion Leader Webinar on Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) and the Potential of Nomacopan to Address Significant Unmet Needs

Retrieved on: 
Tuesday, September 19, 2023
Manchester University NHS Foundation Trust, Hematopoietic stem cell transplantation, Pediatrics, University, Leukotriene B4, Royal Manchester Children's Hospital, Hot game, MD, Division, NHS foundation trust, University of Manchester, Akari, Diagnosis, Hospital, Health, Therapy, LTB4, C5, Pharmaceutical industry

The potential of Akari’s investigational nomacopan, a novel bispecific inhibitor of both complement C5 and leukotriene B4 (LTB4), as a potential treatment for HSCT-TMA also will be discussed.

Key Points: 
  • The potential of Akari’s investigational nomacopan, a novel bispecific inhibitor of both complement C5 and leukotriene B4 (LTB4), as a potential treatment for HSCT-TMA also will be discussed.
  • The Akari management team will present an overview of nomacopan and an update on the two registrational Phase 3 clinical trials investigating nomacopan as a potential treatment option for pediatric and adult HSCT-TMA.
  • A live question and answer session will follow the formal presentations.
  • A replay will be available after the event.

Akari Therapeutics to Host Key Opinion Leader Webinar on Geographic Atrophy and the Potential of Long-Acting PAS-Nomacopan to Address Significant Unmet Needs

Retrieved on: 
Friday, April 14, 2023
Tufts University School of Medicine, Leukotriene B4, Geographic atrophy, Hot game, Akari, Therapy, LTB4, Autoimmunity, Inflammation, Management, Pharmaceutical industry, Ophthalmology, Medicine

Akari’s lead asset is investigational nomacopan, a novel bispecific inhibitor of both complement C5 and leukotriene B4 (LTB4).

Key Points: 
  • Akari’s lead asset is investigational nomacopan, a novel bispecific inhibitor of both complement C5 and leukotriene B4 (LTB4).
  • Long-acting PAS-nomacopan is currently in pre-clinical development as a potential treatment for GA.
  • The webinar event will feature Elias Reichel, M.D., Professor, Department of Ophthalmology, Tufts University School of Medicine.
  • The Akari management team will present an overview and update on the development program investigating long-acting PAS-nomacopan in GA.
    A live question and answer session will follow the formal presentations.

Akari Therapeutics to Attend ARVO 2023, the Annual Meeting of The Association for Research in Vision and Ophthalmology

Retrieved on: 
Tuesday, April 11, 2023
ARVO, Association for Research in Vision and Ophthalmology, Leukotriene B4, Geographic atrophy, Hot game, Research, Therapy, LTB4, Autoimmunity, C5, Inflammation, Pharmaceutical industry, Music, Ophthalmology

NEW YORK and LONDON, April 11, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that management team representatives will attend ARVO 2023, the annual meeting of The Association for Research in Vision and Ophthalmology to meet with researchers, thought leaders, and potential partners.

Key Points: 
  • NEW YORK and LONDON, April 11, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that management team representatives will attend ARVO 2023, the annual meeting of The Association for Research in Vision and Ophthalmology to meet with researchers, thought leaders, and potential partners.
  • Akari’s lead asset is investigational nomacopan, a novel bispecific inhibitor of both complement C5 and leukotriene B4 (LTB4).
  • Long-acting PAS-nomacopan is currently in pre-clinical development as a potential treatment for geographic atrophy.
  • ARVO 2023 will take place in New Orleans April 23 through 27, bringing together approximately 10,000 vision researchers, clinicians, and scientists from around the world for scientific sessions, poster presentations, and invited speaker sessions.

Akari Therapeutics Announces a Case Study from the Phase 3 Part A Clinical Trial of Nomacopan in Pediatric HSCT-TMA Will Be Presented at The European Society for Blood and Marrow Transplantation (EBMT) 49th Annual Meeting

Retrieved on: 
Monday, April 3, 2023
EBMT, Blood, Leukotriene B4, Inflammation, Pediatrics, Part, Hot game, European Society for Paediatric Infectious Diseases, Therapy, LTB4, Autoimmunity, C5, Pharmaceutical industry

NEW YORK and LONDON, April 03, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the upcoming presentation of a case study, Clinical Response to Nomacopan in the Paediatric HSCT-TMA Setting, on Sunday, April 23rd at 8:30 am (GMT+2).

Key Points: 
  • NEW YORK and LONDON, April 03, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the upcoming presentation of a case study, Clinical Response to Nomacopan in the Paediatric HSCT-TMA Setting, on Sunday, April 23rd at 8:30 am (GMT+2).
  • The poster presentation will take place at The European Society for Blood and Marrow Transplantation (EBMT) in Paris, France.
  • Nomacopan is an investigational bispecific inhibitor of both complement C5 and leukotriene B4 (LTB4) currently in Phase 3 clinical trials for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) advancing into pivotal Part B later this year.